The dual-targeted HER1/HER2 tyrosine kinase inhibitor lapatinib strongly potentiates the cardiac myocyte-damaging effects of doxorubicin.
about
Sorafenib-Associated Heart Failure Complicated by Cardiogenic Shock after Treatment of Advanced Stage Hepatocellular Carcinoma: A Clinical Case DiscussionStructure-based design, synthesis and biological testing of piperazine-linked bis-epipodophyllotoxin etoposide analogsMechanisms of Action and Reduced Cardiotoxicity of Pixantrone; a Topoisomerase II Targeting Agent with Cellular Selectivity for the Topoisomerase IIα Isoform.The Myocyte-Damaging Effects of the BCR-ABL1-Targeted Tyrosine Kinase Inhibitors Increase with Potency and Decrease with Specificity.Low level tumor necrosis factor-alpha protects cardiomyocytes against high level tumor necrosis factor-alpha: brief insight into a beneficial paradox.Cardiotoxicity of ErbB2-targeted therapies and its impact on drug development, a spotlight on trastuzumab.Molecular Mechanisms of the Cardiotoxicity of the Proteasomal-Targeted Drugs Bortezomib and Carfilzomib.FGF-2 protects cardiomyocytes from doxorubicin damage via protein kinase C-dependent effects on efflux transporters.
P2860
Q33659820-3EE4E7F6-89E8-4C42-8D6E-D401CB057DF1Q35706214-ACCAC1F8-2E9B-4E15-B43A-2F2AB3FB5E45Q36559677-716A30F9-80BA-4D1E-844D-ADC35C328F2EQ38742779-F088F411-B23E-45FE-875C-9668343A22FFQ38998367-3DDED2AD-EBB7-473A-962A-30EC741DA261Q39344380-36DAEFE2-CFF8-44BA-91E8-90C356E695FDQ48170012-847D7FE5-45C9-4B5F-B550-8D9E1BC43E33Q54454923-AA7722E3-D6DC-4897-B223-8F91221F824F
P2860
The dual-targeted HER1/HER2 tyrosine kinase inhibitor lapatinib strongly potentiates the cardiac myocyte-damaging effects of doxorubicin.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh
2013年學術文章
@zh-hant
name
The dual-targeted HER1/HER2 ty ...... maging effects of doxorubicin.
@en
The dual-targeted HER1/HER2 ty ...... maging effects of doxorubicin.
@nl
type
label
The dual-targeted HER1/HER2 ty ...... maging effects of doxorubicin.
@en
The dual-targeted HER1/HER2 ty ...... maging effects of doxorubicin.
@nl
prefLabel
The dual-targeted HER1/HER2 ty ...... maging effects of doxorubicin.
@en
The dual-targeted HER1/HER2 ty ...... maging effects of doxorubicin.
@nl
P2093
P2860
P1476
The dual-targeted HER1/HER2 ty ...... maging effects of doxorubicin.
@en
P2093
Brian B Hasinoff
Daywin Patel
P2860
P2888
P356
10.1007/S12012-012-9183-X
P577
2013-03-01T00:00:00Z